


**GOLDMAN SACHS EUROPEAN
MEDTECH CONFERENCE 2009**


JOHAN MALMQUIST, CEO

Getinge today

Revenues*: SEK 24 billion
Associates: 12 800



* Estimated revenues 2009 SEK




Structural changes in the Getinge Group for improved earnings growth:

- Increased exposure to therapeutic areas
- Expanding recurring revenue base: from 25% → 45% of total revenue
- Increased exposure to faster growing emerging markets: from 15% → 22% of total revenue

Strategic cornerstones

- Market leadership
- Integrated solutions
- Customer relationships

Sterilization	no 1
Disinfection	no 1
Patient Handling	no 1
Hygiene Systems	no 1
Wound Care/TS	no 2
IPC / DVT	no 1
Surgical Tables	no 1
Surgical Lights	no 1
Ceiling Pendants	no 2
EVH	no 1
Beating heart surgery	no 2
Anastomosis CABG	no 1
Vascular grafts AAA, TAA	no 1
Cardiac Assist IABP	no 1
Ventilation	no 1



Group financial targets

- 15% year over year average growth of pre tax earnings
- To reach and maintain an EBITA-margin of 18-19 %
- Cash flow generation to sustain an external growth rate of 10 %

We believe we can continue to outgrow our market by ~ 2% in coming year

- Increased exposure to faster growing emerging markets
- Sales synergies from recent acquisitions: Huntleigh, Cardiac & Vascular Surgery divisions and Datascope
- Continued investments in product development has expanded our market potential


We believe that we can continue to strengthen our operating margins by:

- Ongoing realization of cost synergies from recent and pending acquisitions. Declining integration costs.
- Improved cost position through supply chain enhancement
- Exposure to product segments with higher profitability
- Introduction of new products with higher profitability potential

Actual	2006	2007	2008	Target	Comments
EBITA-margin	15.5%	16.1%	17.8%	18-19%	upward revision

Integration of Datascope

- Cost synergies of 170 MSEK from 2010 onwards
 - Redundant HQ structure
 - US delisting
 - Merged sales companies
- Revenue synergies from geographical and product complementarities



Integration of Cardiac and Vascular surgery divisions

- Cost synergies of 100 – 120 MSEK from 2010 onwards
 - Plant consolidation and administrative efficiencies
- Revenue synergies from geographical and product complementarities



Innovation and product development has not been fully exploited as a means of increasing growth across all business areas



Cardiohelp. World's smallest, portable heart and lung support device.



Fusion graft. Reinforced vessel implant made of PFTE with an external textile casing.



FLOW-i. Anaesthesia system with superior clinical performance and cost of ownership.



ED-flow. High capacity disinfecter for flexible endoscopes.

External growth will continue to play an important role in realizing both strategic and financial targets:

Medical Systems

- Cardiovascular: Vascular interventions and Cardiac assist
- Surgical Workplaces: Surgical tools

Extended Care

- Therapeutic surfaces/wound care USA
- Technology and product bolt-on's

Infection Control

- Consumables/Chemistry
- Technology and product bolt-on's

Outlook 2009

- We expect revenues to grow organically by 2 – 3%
- We expect pre tax profit to grow by 15% including integration costs of 200 MSEK relating to Datascope acquisition
- We expect net gearing to improve significantly